Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 2/20 | 0.78 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.74 |
| ▸ | CA2 | P00918 | 8/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 7/20 | 0.51 |
| ▸ | CA9 | Q16790 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079067 | 0.88 | PRMT1 (1.00) | PRMT1SIRT1CA2CASP6CTDSP1 | |
| SCHEMBL29349608 | 0.88 | PRMT1 (1.00) | PRMT1SIRT1CA2CASP6CTDSP1 | |
| SCHEMBL2679101 | 0.88 | PRMT1 (1.00) | PRMT1SIRT1CA2CASP6CTDSP1 | |
| SCHEMBL6079012 | 0.86 | PRMT1 (0.76) | PRMT1SIRT1CA2KMT2ACASP6 | |
| SCHEMBL29352560 | 0.85 | PRMT1 (1.00) | PRMT1SIRT1CA2KMT2ACASP6 | |
| SCHEMBL6079061 | 0.85 | PRMT1 (1.00) | PRMT1SIRT1CA2KMT2ACASP6 | |
| SCHEMBL1807286 | 0.81 | CASP6 (0.59) | PRMT1SIRT1CA2KMT2ACASP6 | |
| SCHEMBL10014033 | 0.80 | PRMT1 (0.84) | PRMT1SIRT1CA2CASP6CTDSP1 | |
| SCHEMBL18134576 | 0.80 | PRMT1 (0.84) | PRMT1SIRT1CA2CASP6CTDSP1 | |
| SCHEMBL11342001 | 0.79 | PRMT1 (0.82) | PRMT1SIRT1CA2CASP6CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071231-B2 | Naphthalene ureas as glucose uptake enhancers | TELIK, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1181271-B1 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | SPEVAK WAYNE R (US) | 2003-07-17 | — | — | US | disclosed |
| US-6458998-B1 | NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS | TELIK, INC. | 2002-10-01 | — | — | US | disclosed |
| CN-1364156-A | Novel naphthalene ureas as glucose uptake enhancers | TELIK INC (US) | 2002-08-14 | — | — | CN | disclosed |
| EP-1181271-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | Telik, Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000071506-A9 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000071506-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | GPR119, SLC2A8, SLC2A1 | PRMT1 2899/4885SIRT1 1910/4885CA2 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.